OncoGenex Pharmaceuticals, Inc, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of custirsen (OGX-011) when administered in combination with cabazitaxel (Jevtana Kit)/prednisone for the treatment of men with metastatic...
Noncompliance appears to be a major challenge for active surveillance, according to the results of long-term follow-up of patients with prostate cancer presented at the European Association of Urology 29th Annual Congress in Stockholm. Over a quarter of men dropped out of the active surveillance...
Men with localized prostate cancer that is at risk of growing and spreading have a lower risk of disease progression and recurrence if they are treated with radiotherapy combined with androgen-deprivation therapy, according to new research. The findings, which were presented at the 33rd Conference...
A new genetic signature to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, according to a study presented at the 33rd Conference of the European Society for Radiotherapy and Oncology in...
Dose-escalated intensity-modulated radiotherapy with use of a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a study by Hoffman et al published in the International Journal ...
A new study suggests that levels of bisphenola A (BPA) in men’s urine may be a marker of prostate cancer and that low levels of BPA exposure can cause cellular changes in both nonmalignant and malignant prostate cells. The research, published in PLOS ONE, provides the first evidence that...
An observational study from UCLA’s Jonsson Comprehensive Cancer Center comparing robotic-assisted surgery to traditional surgery for prostate cancer found that patients who had robotic surgery had fewer instances of cancer cells remaining after surgery and less need of additional cancer...
A multicenter study led by Fred Hutchinson Cancer Research Center has found that high-dose supplementation with both the trace element selenium and vitamin E may increase the risk of high-grade prostate cancer. This risk is dependent upon a man’s selenium status prior to taking the...
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute. The study, published in the journal Clinical Cancer Research, adds...
Men with short-ended chromosomes in the immune cells in their blood were at increased risk for aggressive prostate cancer compared with men with long-ended chromosomes in blood immune cells, according to results presented at the 12th Annual AACR International Conference on Frontiers in Cancer...
Men with advanced prostate cancer are now living longer than ever, and it is estimated that one in six U.S. men will be diagnosed with prostate cancer in their lifetime. However, little research has been conducted to understand the psychosocial needs of these men and their caregivers after...
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
A team of researchers led by Janet Stanford, PhD, of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production—both of which impact immune function—increase the risk ...
Prostate cancer is one of the most common forms of cancer in men and the leading cause of cancer deaths in white, African American, and Hispanic men, according to the Centers for Disease Control. However, it remains unclear why, despite treatment, some prostate cancers progress and may become...
A team of researchers from UC Davis, UC San Diego, and other institutions has identified a key mechanism behind aggressive prostate cancer. Published online today in Nature, the study shows that two long noncoding RNAs, PRNCR1 and PCGEM1, activate androgen receptors, circumventing...
A new study led by researchers at Sanford-Burnham Medical Research Institute reveals how a promising anticancer compound called SMIP004 specifically kills prostate cancer cells by compromising their ability to withstand environmental stress. The study, recently published in Oncotarget, uncovered...
Men who decide to be screened for prostate cancer and those who forgo PSA screening stick with their decisions after receiving materials explaining the risks and benefits of the test, according to a study published in JAMA Internal Medicine. The study examined both Web-based and printed tools aimed ...
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy was associated with a significantly increased risk of acute kidney injury, with variations observed with certain types of androgen deprivation therapies, according to a study in the ...
Researchers at Albert Einstein College of Medicine of Yeshiva University have found that nerves play a critical role in both the development and spread of prostate tumors. Their findings, using both a mouse model and human prostate tissue, may lead to new ways to predict the aggressiveness of...
A second large, prospective study by scientists at Fred Hutchinson Cancer Research Center has confirmed the link between high blood concentrations of omega-3 fatty acids and an increased risk of prostate cancer. Study Details Published online in the Journal of the National Cancer Institute, the...
Among men who had undergone radical prostatectomy, daily consumption of a beverage powder supplement containing soy protein isolate for 2 years did not reduce or delay development of biochemical recurrence of prostate cancer compared to men who received placebo, according to a study in the July 10...
A study of more than 1,800 men aged 52 to 62 suggests that African Americans diagnosed with very low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches. Although prior studies have found it safe to...
Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy (IMRT) and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these...
Many men with low-risk, localized prostate cancers can safely choose active surveillance or watchful waiting instead of undergoing immediate treatment and have better quality of life while reducing health-care costs, according to a study by researchers at Dana-Farber Cancer Institute and...
An Australian study has identified a subgroup of prostate cancer cells that survive androgen deprivation therapy and could contribute to prostate cancer recurrence. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease development,...
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow. In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling,...
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for castration-resistant metastatic prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout...
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
On May 15, 2013, the U.S. Food and Drug Administration approved radium Ra 223 dichloride (Xofigo) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. Radium-223 dichloride is an...
Obese men were more likely to have precancerous lesions detected in their benign prostate biopsies compared with nonobese men and were at a greater risk for subsequently developing prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the...
Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds. Previous smaller studies had indicated that intermittent androgen deprivation therapy might be just as good...
A research team jointly led by scientists from Cedars-Sinai Medical Center and the University of California, Los Angeles, has enhanced a device they developed to identify and “grab” circulating tumor cells (CTCs) that break away from cancers and enter the blood, often leading to the...
Men with Lynch syndrome face a higher lifetime risk of developing prostate cancer and appear to develop the disease at an earlier age, according to a new study led by researchers at the University of Michigan Comprehensive Cancer Center. Results of the study appear online in the Journal of Clinical ...
Surgery offers better survival benefit for men with localized prostate cancer, according to a large observational study, conducted by a group of researchers in Sweden and the Netherlands. The study, “Comparative oncologic effectiveness of radical prostatectomy and radiotherapy in prostate...
New research from The Cancer Institute of New Jersey suggests that more stringent criteria may be needed for African American men with prostate cancer when considering active surveillance of the disease. The findings, published in the latest online version of Urology found that the prevalence ...
Men with low-risk prostate cancer who previously had to choose between aggressive treatment, with the potential for significant side effects, and active surveillance, with the risk of disease progression, may have a new option. Focal laser ablation uses precisely targeted heat, delivered through a...